PF-Atlas › Clinical Trials › NCT01570764
Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease
Cyclophosphamide · Phase 3
Registry ID
NCT01570764
Phase
Phase 3
Status
Completed
Drug / intervention
Cyclophosphamide
Sponsor
Assistance Publique - Hôpitaux de Paris
Start
2013-01-14
Enrollment
40
Locations
1
About this trial
By including in this study patients with significant worsening of their lung volumes and / or their DLCO (carbon monoxide diffusing capacity) in the previous year, on the basis of an open retrospective study we recently conducted, we hope to demonstrate that a strategy combining prednisone and intravenous cyclophosphamide therapy is accompanied by an increase in the frequency stabilization / improvement of lung volumes and / or DLCO of patients at 12 months of 15% in the placebo and prednisone cyclophosphamide 50% in cyclophosphamide and prednisone.We also hope to demonstrate significant decrease in the number of patients excluded for failure in the CYC arm as compared to the placebo arm.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT01570764 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.